The clinical spectrum of pneumococcal infections ranges from sinusitis and acute otitis media through to pneumonia and meningitis, with pneumonia being the most common serious presentation in adults [5, 7] .
Pneumococcal infections are classified as invasive pneumococcal disease (IPD) if
Streptococcus pneumoniae is isolated from a normally sterile site such as the bloodstream or meninges [7] . Therefore, IPD is a microbiological rather than a clinical diagnosis, requiring specific testing usually within a secondary (i.e., hospital) setting. The term IPD is predominantly used by epidemiologists, vaccinologists, and paediatricians. Bacteraemic pneumonia is the most common IPD, comprising the overwhelming majority of adult cases [8] [9] [10] .
S. pneumoniae is a leading cause of communityacquired pneumonia (CAP; i.e., pneumonia in individuals who have not been recently hospitalised) and thus most of the burden of serious pneumococcal infection in adults relates to pneumonia [5, 7] . The incidence of CAP varies across both studies and countries; however, publications consistently report increasing incidence with increasing age [5, 11] . Therefore, as the mean age of the population increases within Europe, it is expected that the burden of CAP is likely to increase. The burden of pneumococcal infections is also exacerbated by increasing numbers of individuals with chronic disease or HIV infection [12] [13] [14] [15] , and has remained high in adults aged >50 years despite the use of the 23-valent purified capsular polysaccharide vaccine (PPV-23) in adults and the pneumococcal conjugate vaccine (PCV) in children [16] .
The reported overall incidence of IPD in children and adults ranges from 10 to 23.2 per
INTRODUCTION
Infectious diseases in elderly people are a significant cause of morbidity and mortality in Europe in spite of the availability of antibiotics and vaccines for conditions such as pneumococcal infections, influenza, herpes zoster, and hepatitis A and B [1] [2] [3] [4] [5] . Multiple changes occur with age in both innate and adaptive immune systems, and this waning immunity (known as 'immunosenescence') as well as physiological changes associated with ageing make elderly individuals especially vulnerable to infectious diseases [2, 6] .
Pneumonia and influenza, in particular, tend to occur with greater severity in elderly individuals than in younger adults and are associated with poorer outcomes [4] . Adult populations at increased risk of pneumococcal infection are the elderly, those with chronic disease, such as lung or heart disease, diabetes, sickle cell anaemia, or asplenia, and those with compromised immune status, such as HIV-infected individuals [7] . countries (France, Germany, Italy, Spain, the UK, Austria, Greece, Portugal, Norway, Sweden, Switzerland, Finland, and Denmark). Mortality associated with IPD increases with age in adults, reaching 10.6% in patients ≥65 years of age and 20.6% in those aged ≥80 years [10, 17] .
Primary care physicians (including internists
The following factors have been identified as being associated with fatal outcomes in patients with IPD: increasing comorbidity scores, neutropenia, HIV infection, chronic respiratory disease, and chronic liver disease [21] .
In line with the significant burden of pneumococcal infections, recommendations for vaccinating elderly and vulnerable individuals against pneumococcal infections are available in most European countries. There is, however, considerable variability between countries concerning individuals regarded at risk of invasive pneumococcal infections, and these disparities appear to impact rates of pneumococcal vaccination across Europe.
Higher rates of vaccine use have been reported in countries with age-based recommendations and public reimbursement (e.g., UK) than in those countries only recommending at-risk individuals (e.g., The Netherlands, Denmark, Portugal, and France) [22, 23] . Lack of reimbursement may also explain low rates of vaccination in some countries (e.g., Austria, Finland, and Norway) with age-based recommendations [22] .
The aim of this article is to describe the current level of awareness of pneumococcal infection among primary care physicians and specialists, as well as physicians' and the general publics' attitudes towards vaccination, based on findings from a European survey of physicians and individuals aged >50 years from the general public.
MATERIALS AND METHODS

Survey
A physician survey was conducted to determine pneumococcal disease awareness and attitudes to vaccination in 13 Western European
Participant Eligibility and Recruitment
Physicians were recruited from a European panel, which included 87,048 primary care doctors and 18,948 specialists (as defined above). Practicing physicians were included in the survey if they were aged between 30 and 65 years (inclusive), had been in practice for ≥3 years, and spent ≥50% of their working time in direct patient care. Primary care physician and specialist selection was based on age and sex distribution according to country demographics and regional distribution. E-mail invites were sent to a sample of panellists, with e-mail and telephone follow-up to achieve the target number of participants. Survey respondents were paid for their participation.
Adults aged >50 years were recruited via random house sampling in Germany, and via interviewer selection, ensuring that quotas were fulfilled and that the individual was willing to participate, in Spain. Within the remaining countries, participants were recruited using the national phonebook information. The sample population was designed to reflect the socio-demographic structure of the national population available in each country. Adults aged >50 years who were representative of each country's demographic, in terms of age, sex, region, and socio-economic level, were selected for inclusion into the survey.
In Germany, interviews were conducted faceto-face at the respondent's residence. In Spain, qualifying participants were invited for interview in the street and then came to a room for the interview. Members of the general public did not receive payment for their participation.
Both physicians and adults were excluded from the survey if they or someone in their family worked full-time in a pharmaceutical or market research company, or if they had taken part in a survey in the field of vaccination within the past 3 months.
Statistical Analysis
The survey findings were summarised descriptively with the percentage of primary care physicians, specialists, or individuals aged >50 years calculated for each response. Overall percentages (i.e., for all 13 countries) for each of these three groups were calculated, as well as percentages in each country. Mean frequency and severity scores (based on 7-point scales)
for pneumococcal infections and some other common infectious diseases were also calculated for physicians. Statistical analysis of the levels of spontaneous awareness and probed awareness (i.e., physicians were presented with a list of terms) among the physicians were undertaken, using a two-sided t-test to compare awareness levels between the pneumococcal infection terms.
RESULTS
Study Populations
A total of 1,300 primary care physicians A total of 6,534 adults aged >50 years participated in the survey (around 500 individuals from each of the 13 countries). Across these countries, the proportion of male individuals varied from 45% to 50%. In Germany, 52%
were aged ≥60 years and, within the remaining 12 countries, between 31% (Switzerland) and 60% (Portugal) were aged ≥65 years. The proportion of retired individuals ranged from 29% in Switzerland to 63% in France.
Disease Awareness Among Primary Care
Physicians and Specialists
Pneumonia was the most well-known of the pneumococcal infections. When physicians were asked to name pneumococcal infections, significantly more physicians named pneumonia than other pneumococcal infections (P < 0.001):
78% of primary care physicians and 78% of specialists named pneumonia, 54% and 60% named meningitis, and 25% and 36% named sepsis/septicaemia, respectively. When presented with a list of pneumococcal infections, 93% of primary care physicians and 96% of specialists stated that they knew about non-invasive pneumococcal pneumonia (Table 1) , with awareness levels ranging from 83% to 99% and 91% to 100%, respectively, across the 13 countries (data not shown). IPD, however, was the least well known term (P < 0.001 for IPD vs. other terms); only 50% of primary care physicians Invasive pneumococcal diseases 50* 71* a Physicians were presented with a list of terms and asked which of them they knew. * P < 0.001 versus other terms
The mean severity scores as rated by primary care physicians and specialists, respectively, varied from 5.7 to 6.6 and from 5.6 to 6.6 (based on the 7-point scale) for infections classified as IPD, as well as for the term IPD itself. Primary care physicians perceived pneumococcal sepsis and meningitis as very severe diseases (severity score: 6.6 for both) compared with a severity score of 4.9 for non-invasive pneumococcal pneumonia.
The frequency of pneumococcal infections as reported by specialists was higher than that reported by primary care physicians (mean frequency scores ranging from 2.8 to 4.7 and from 2.6 to 3.9, respectively, on a 7-point scale, Fig. 1 Perceived severity of pneumococcal infections (light blue bars) compared with other infectious diseases (dark blue bars) among primary care physicians and specialists. Physicians (primary care physicians: n = 1,300; specialists: n = 926) were asked to grade the severity of the above infectious diseases using a 7-point scale, where 7 is extremely severe and 1 is not severe at all. e gure shows mean severity scores. e term meningitis refers to meningitis of unspeci ed aetiology Specialists Primary care physicians Mean severity score M ean severity score where 7 was extremely frequent), and both groups of physicians perceived pneumococcal infections to be less frequent than other vaccinepreventable diseases such as gastroenteritis and influenza, which both had mean severity scores >5 (Fig. 2) . The mean frequency scores for IPD (2.7 and 3.2), as rated by primary care physicians and specialists, respectively, were lower than those for non-invasive pneumococcal pneumonia (3.9 and 4.7) and bacteraemic pneumococcal pneumonia (3.3 and 3.9).
Physicians' Attitudes to Vaccination
Over 60% of primary care physicians and specialists selected the following as factors Fig. 2 Perceived frequency of pneumococcal infections (light blue bars) compared with other infectious diseases (dark blue bars) among primary care physicians and specialists. Physicians (primary care physicians: n = 1,300; specialists: n = 926) were asked to grade the frequency of the above infectious diseases using a 7-point scale, where 7 is extremely frequent and 1 is not frequent at all. e gure shows mean frequency scores. e term meningitis refers to meningitis of unspeci ed aetiology For pneumococcal vaccination, the patient's health condition was also a key factor for recommending/prescribing vaccination (rated 6 or 7 on a 7-point scale by 74% of primary care physicians and specialists), as were healthauthority recommendations, the patient's age, and tolerability of the vaccine (Fig. 3) includes physicians' definitions of these groups).
The main factors leading to a physician sometimes not recommending pneumococcal vaccination were that pneumococcal vaccination concerns only a subgroup of patients (selected by 67% and 77% of primary care physicians and specialists, respectively), the physician's mindset (i.e., vaccination is not at the top of the physician's mind), and lack of time (Table 2) .
General Public's Attitudes to Vaccination
Of the adults aged >50 years included in the survey, 70%, 49%, and 10% indicated that they had received tetanus/diphtheria, influenza, and/or pneumococcal vaccines, respectively, since the age of 18 years (see Supplementary Material - Table 1 Paitent's health condition 74
Recommendation from health authorities 61 Adults aged >50 years were asked to indicate whether they agreed or disagreed with the above statements; 7 indicates 'agree strongly' and 1 indicates 'disagree strongly' . (Table 5) .
DISCUSSION
Disease Awareness
Findings from this survey highlight the variability in knowledge/awareness levels of pneumococcal conditions amongst primary care physicians and specialists. Pneumonia was the most well-known of the pneumococcal infections, which is in line with the fact that pneumonia is the most common serious presentation of pneumococcal infections.
The survey results, however, highlighted the relatively low knowledge of the term IPD. This may reflect the fact that IPD is not currently considered a relevant classification in everyday practice. This is perhaps not surprising given that IPD is not an 'independent' entity, except in rare cases of primary bacteraemia [26] and, also, that no significant differences have been identified in outcomes and mortality rates between CAP with or without pneumococcal bacteraemia [27] .
Physicians within the survey considered pneumococcal infections to be severe. This an annual hospitalisation rate of 1.09 cases per 1,000, with a case-fatality rate of 11.6% for pneumococcal pneumonia [28] . Similarly, a 30-day mortality rate of 9.6% was reported in a UK observational study conducted in adults 
Importance of Vaccination Programmes
Given the significant burden of pneumococcal infections, especially in elderly individuals, pneumococcal vaccination should be an important contribution to infectious disease prevention in an approach to lifelong health.
As previously discussed, recommendations for vaccinating elderly and vulnerable individuals against pneumococcal infections vary from country to country, and this appears to impact coverage levels [22] . In Europe, PCV-13 is now available in some countries for the prevention of IPD in individuals aged >50 years [51] , and for the prevention of IPD, pneumonia, and otitis media in infants and children from 6 weeks up to the age of 17 years [52] . PCV-10 is also available in Europe for immunisation against IPD and acute otitis media in infants and children from 6 weeks up to 5 years of age [53] .
Immunological responses following PCV-13 
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